Jonathan Allan - May 20, 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
GENERAL COUNSEL & CORP SEC
Signature
/s/ Jonathan Allan
Stock symbol
STOK
Transactions as of
May 20, 2024
Transactions value $
-$68,532
Form type
4
Date filed
5/22/2024, 04:15 PM
Previous filing
Apr 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $60.8K +8.6K +330.99% $7.07 11.2K May 20, 2024 Direct
transaction STOK Common Stock Sale -$129K -8.6K -76.8% $15.04 2.6K May 20, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Stock Option (Right to Buy) Options Exercise $0 -8.6K -25% $0.00 25.8K May 20, 2024 Common Stock 8.6K $7.07 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2023 by the reporting person.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
F3 The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.